Low Viscosity EMD Composition for Bone Graft Bioactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone graft materials face limitations such as limited availability, immune risks, mechanical weaknesses, and variable success rates in bone regeneration, particularly in periodontal tissue diseases, due to issues with autografts, allografts, xenografts, and synthetic substitutes, which often result in incomplete bone healing and resorption.
Innovation Solution
A low viscosity composition comprising isolated enamel matrix proteins (EMD) is applied to porous bone graft materials, enhancing bioactivity and osteoconduction by maintaining the proteins' stability and promoting homogeneous coverage, thereby improving bone regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enamel matrix proteins are applied to bone graft materials, then bioactivity and osteoconduction are enhanced, but the composition viscosity becomes too high for homogeneous coverage
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the composition to a specific range (pH 3.8-4.2) to optimize the balance between viscosity and bioactivity. This pH adjustment allows the enamel matrix proteins to maintain stability and promote homogeneous coverage while preserving their osteoinductive properties, thus resolving the contradiction between high viscosity and ease of application.
2Productivity
If enamel matrix proteins are applied to bone graft materials, then bone regeneration is improved, but protein stability is compromised at suboptimal pH
Solution Approach 1:
The patent utilizes parameter changes by precisely controlling the pH within the range of 3.8-4.2, which is the optimal range for maintaining enamel matrix protein stability. Within this pH window, the proteins retain their folded conformation and biological activity, ensuring both protein stability and effective bone regeneration without degradation.
Solution Approach 2:
The patent applies preliminary action by pre-adjusting the pH of the composition before application to ensure proteins are in their stable, folded state. This preliminary pH optimization prevents protein denaturation and aggregation during storage and application, preserving regenerative properties before the proteins contact the bone graft material.
3Reliability
If enamel matrix proteins are applied to bone graft materials, then osteoconduction is enhanced, but homogeneous coverage is difficult to achieve
Solution Approach 1:
The patent applies parameter changes by optimizing the pH to 3.8-4.2, which reduces the composition viscosity to a manageable level. This viscosity reduction enables the composition to flow uniformly and coat the bone graft material surfaces homogeneously, ensuring consistent enamel matrix protein distribution and reliable osteoconduction across the entire graft surface.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioactivated bone graft material demonstrates enhanced biocompatibility and osteoconduction, leading to improved bone regeneration and reduced resorption, with the EMD proteins precipitating in a folded state to maintain regenerative properties and coat the graft homogeneously, preventing flap collapse and promoting tissue integration.
Implementation Method 1
the EMD proteins precipitating in a folded state to maintain regenerative properties and coat the graft homogeneously
Data Source
AI summary
The present invention discloses a low viscosity composition comprising enamel matrix derivative (EMD) proteins in a suitable pharmaceutical carrier, said composition having a pH between pH 3.8-4.2, and a viscosity of less than 50 mPa s at 22° C., which, when applied to a porous bone graft material, improves and/or enhances bioactivity and osteoconduction of said bone graft material. The present invention consequently discloses a bone graft material which has been bioactivated using a low viscosity composition comprising enamel matrix derivative (EMD) proteins and which displays enhanced biocompatibility and improved bone regeneration after implantation.